Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women

Journal of Medical Investigation

Volumn 54, Issue 1-2, 2007, Pages 35-40

  Takata, Shinjiro ^a   Abbaspour, Aziz ^a   Yonezu, Hiroshi ^b   Yasui, Natsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Mitoyo General Hospital   (Japan)

Author keywords

Alendronate; Alfacalcidol; Bone mineral content; Bone mineral density; Markers of bone mineral metabolism

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; COLLAGEN TYPE 1; 1-HYDROXYCHOLECALCIFEROL; ALKALINE PHOSPHATASE; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; HYDROXYCOLECALCIFEROL; PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; HUMAN; LUMBAR VERTEBRA; MAJOR CLINICAL STUDY; OSTEOPOROSIS; THERAPY EFFECT; TREATMENT OUTCOME; BLOOD; DRUG EFFECT; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; URINE;

AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES;

EID: 34247846427     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.54.35     Document Type: Article

References (15)

1. Anonymous : Osteoporosis prevention, diagnosis, and therapy. NIH consensus development panel on osteoporosis prevention, diagnosis and therapy. JAMA 285 : 785-795, 2001
2. Smith CB, Smith DA : Relationship between age, mineral density and mechanical properties of human femoral compacta. Acta Orthop Scand 47 : 496-502, 1976
3. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H : A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporosis Int 10 (3) : 183-192, 1999
4. Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ : Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 338 : 485-492, 1998
5. Ettinger MP : Aging bone and osteoporosis : strategies for preventing fractures in the elderly. Arch Intern Med 163 (18) : 2237-2246, 2003
6. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE : Randomized trial of effect on alendronate on risk of fracture in women with existing vertebral fractture : Fracture Intervention Trial Research Group. Lancet 348 : 1535-1541, 1996
7. Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T, Ogawa N : Effects of 1 alfa-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54 (5) : 370-376, 1994
8. Tanizawa T, Imura K, Ishii Y, Nishida S, Takano Y, Mashiba T, Endo N, Takahashi HE : Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures : a retrospective study. Osteoporosis Int 9 (2) : 163-170, 1999
9. Russell-Aulet M, Wang J, Thornton J, Pieson RNJr: Comparison of dual-photon absorptiometry systems for total-body bone and soft tissue measurements : dual energy X-rays versus Gadolinium 153. J Bone Miner Res 6 (4) : 411-5, 1991
10. Einhorn TA : Bone strength. The bottom line. Calcif Tissue Int 51 : 333-339, 1992
11. Frost HM : Dynamics of bone remodeling. In : Frost HM (ed) Bone biodynamics. Little Brown, Boston, 1964, pp.315-334
12. Recker R, Masarachia P, Santora A, Howard T, Chavassieux P, Arlot M, Rodan G, Wehren L, Kimmel D : Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin 21 (2) : 185-194, 2005
13. Nuti R, Martini G, Giovani S, Valenti R : Effect of treatment of with calcitriol combined with low-dosage alendronate in involutional osteoporosis. Clin Drug Invest 19 (1) : 55-61, 2000
14. Frediani B, Allegri A. Bisogno S, Marcolongo R : Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis-two years of continuous treatment. Clin Drug Invest 15 (3) : 735-744, 1998
15. Recker R, Lips P, Felsenberg D, Lippuner K, Benhamou L, Hawkins F, Delmas PD, Rosen C, Emkey R, Salzmann G, He W, Santora AC : Alendronate with and without cholecalciferol for osteoporosis : result of a 15-week randomized controlled trial. Curr Med Res Opin 22 (9) : 1745-1755, 2006